Announcements Trials
Browse Landscape

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 2934Neoplasms 2633Lung Neoplasms 1370Colorectal Neoplasms 1332Prostatic Neoplasms 1216Carcinoma, Non-Small-Cell Lung 1080Carcinoma, Hepatocellular 783Stomach Neoplasms 721Pancreatic Neoplasms 704Ovarian Neoplasms 586Colonic Neoplasms 534Uterine Cervical Neoplasms 497Head and Neck Neoplasms 496Rectal Neoplasms 472Melanoma 467Multiple Myeloma 463Esophageal Neoplasms 422Neoplasm Metastasis 418Brain Neoplasms 405Lymphoma 399Precursor Cell Lymphoblastic Leukemia-Lymphoma 398Urinary Bladder Neoplasms 387Leukemia, Myeloid, Acute 387Leukemia 339Carcinoma, Renal Cell 329Liver Neoplasms 320Endometrial Neoplasms 319Hematologic Neoplasms 313Recurrence 298Disease 275

Interventions

trastuzumab deruxtecan 1Isovaleryl-CoA Dehydrogenase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × HER2 Overexpression × Clear all
NCT07035353 2025-06-25

A Real-world Clinical Study of T-DXd for the Treatment of Chinese Patients With HER2 Overexpressing and HER2 Underexpressing Advanced Breast Cancer

Tianjin Medical University Cancer Institute and Hospital

Not yet recruiting
200 enrolled
Breast

HER2 Overexpression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡